IN8bio Approves Key Proposals at Annual Meeting

IN8bio ( (INAB) ) has issued an update.

IN8bio, Inc. held its annual meeting of stockholders on May 8, 2025, where several key proposals were voted on. All three director nominees were elected to serve until the 2028 annual meeting, the appointment of CohnReznick LLP as the independent registered public accounting firm for 2025 was ratified, and a reverse stock split proposal was approved. These decisions are likely to impact the company’s governance and financial structuring.

Spark’s Take on INAB Stock

According to Spark, TipRanks’ AI Analyst, INAB is a Underperform.

IN8bio’s stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.

To see Spark’s full report on INAB stock, click here.

More about IN8bio

Average Trading Volume: 5,360,065

Technical Sentiment Signal: Sell

Current Market Cap: $13.37M

Learn more about INAB stock on TipRanks’ Stock Analysis page.